亚太地区免疫诊断市场预测至 2030 年 - 区域分析 - 按产品（酵素连结免疫吸附测定、化学发光免疫测定、放射免疫测定等）、临床适应症和最终用户

亚太免疫诊断市场预计将从2023年的24.099亿美元成长到2030年的42.5235亿美元。预计2023年至2030年CAGR为8.5%。

免疫诊断技术进步推动亚太工业机器人市场

当前免疫诊断的趋势是具有商业化潜力的微流控和磁珠。这些敏感、具体且节省时间的方法对于理解和诊断健康状况（例如传染病、代谢紊乱和心臟问题）至关重要。

免疫诊断解决方案的不断增加的应用鼓励了针对精准健康的标靶治疗和疗法的开发。着名的市场参与者也推广检测技术、微流体和磁珠。对于免疫测定，磁性颗粒（例如 Sera-Mag 磁珠）为基于板的 ELISA 提供了便捷的替代方案，因为两者都依赖相同的测定原理。 Merck KGaA 推出了 Magna Chip Protein A 磁珠。这种重组蛋白 A 与磁珠共价结合，用于染色质免疫沉淀（晶片测定），为使用者提供比琼脂糖微珠更快、可重复且更有效的免疫复合物收集试剂。

在微流体学中，一些免疫诊断针对单一生物标记。然而，最近的趋势表明，根据复杂性和早期可靠诊断的需要，可以检测多种分析物。

2023 年 9 月，西门子 Healthineers 发布了带有 CE 标誌的新型 SARS-CoV-2/FluA/FluB/HRSV 检测、PCR 检测以及 CLINITEST 快速 COVID-19 + 流感抗原检测。新的 FTD SARS-CoV-2/FluA/FluB/HRSV 检测能够对季节性呼吸道病原体进行全面、半自动化的分子检测。组合 PCR 测试可检测和区分临床相关病毒，例如 SARS-CoV-2、甲型流感、乙型流感和 HRSV A/B。

亚太地区免疫诊断市场概况

根据Statista统计，2020年中国很大一部分人口患有慢性病。中国60岁以上人口死亡中近80%是由慢性非传染性疾病引起，其中最严重的是缺血性心臟病、中风、慢性阻塞性肺病(COPD) 和II 型糖尿病。根据《中国蓝图》显示，免疫诊断已超过生化诊断（占27%），体外诊断（IVD）市场已成为中国主流。但与已开发国家相比，我国免疫诊断市场的替代生化诊断仍有拓展空间，根据多家机构的统计资料，生化与免疫诊断的平均比例约为1：2。随着技术创新的进步以及对高端测试的需求不断增长，诊断预计将巩固其主流地位。

此外，组织之间在开发和生产检测方法方面的合作正在不断增加。例如，2023 年 12 月，Ortho Clinical Diagnostics Trading 和上海麦康生物技术有限公司签署了一项协议，作为合资企业的一部分，在中国开发和製造 VITROS 免疫诊断平台的检测方法。 Ortho Clinical Diagnostics Trading 在开发和设计用于 POC 设置、临床实验室和输血医学的体外诊断 (IVD) 技术方面的专业知识将推动亚太地区免疫诊断市场在未来几年的成长。

亚太地区免疫诊断市场收入及 2030 年预测（百万美元）

亚太地区免疫诊断市场细分

亚太地区免疫诊断市场分为产品、临床适应症、最终用户和国家。

根据产品，亚太免疫诊断市场分为酵素连结免疫吸附测定（ELISA）、化学发光免疫测定（CLIA）、放射免疫测定（RIA）等。 2023年，酵素连结免疫吸附测定（ELISA）领域在亚太免疫诊断市场中占据最大份额。化学发光免疫分析 (CLIA) 领域进一步细分为维生素 D 分析市场、HIV 检测市场、HIV a/ab 组合分析市场和其他测试。

根据临床适应症，亚太免疫诊断市场分为传染病、爱滋病毒、内分泌、胃肠道、代谢等。 2023年，传染病领域在亚太免疫诊断市场中占据最大份额。传染病细分为 COVID-19、结核病、莱姆病、感染管理、寨卡病毒、密螺旋体、火炬、麻疹和腮腺炎、水痘带状疱疹病毒和 EB 病毒。内分泌科进一步细分为高血压、生长、糖尿病、甲状腺和生殖内分泌。

根据最终用户，亚太地区免疫诊断市场分为医院、诊所、诊断实验室、学术和研究机构等。 2023年，医院细分市场在亚太免疫诊断市场中占据最大份额。

依国家/地区划分，亚太地区免疫诊断市场分为中国、日本、印度、澳洲、韩国和亚太地区其他地区。 2023年，中国在亚太免疫诊断市场中占最大份额。

雅培实验室；生物梅里埃公司；丹纳赫公司； DiaSorin SpA； F.霍夫曼-拉罗氏有限公司；珀金埃尔默公司；深圳迈瑞生物医疗电子有限公司；西门子医疗保健有限公司；斯瓦尔生命科学公司；和 Thermo Fisher Scientific Inc 是亚太地区免疫诊断市场上的一些领先公司。

概述
按临床适应症分類的亚太地区免疫诊断市场份额 - 2022 年和 2030 年 (%)
传染性疾病：
- 概述
  - 新冠肺炎
  - 结核
  - 莱姆病
  - 感染管理
  - 寨卡病毒
  - 密螺旋体属
  - 火炬
  - 麻疹和腮腺炎
  - VZV
  - EB病毒
肝炎+爱滋病毒：
- 概述
胃肠道
- 概述
代谢紊乱
- 概述
内分泌科
- 概述
- 高血压
  - 概述
- 生长
  - 概述
- 糖尿病
  - 概述
- 甲状腺
  - 概述
- 生殖内分泌学
  - 概述
其他的
- 概述

第 9 章：亚太地区免疫诊断市场分析 - 最终用户

概述
按最终用户分類的亚太地区免疫诊断市场份额 - 2022 年和 2030 年 (%)
医院
- 概述
诊所
- 概述
诊断实验室
- 概述
学术及研究机构
- 概述
其他的
- 概述

第 10 章：亚太地区免疫诊断市场 - 2030 年收入与预测 - 国家分析

概述

第 11 章：亚太地区免疫诊断市场 - 产业格局

概述
无机成长策略
- 概述
有机成长策略
- 概述

第 12 章：公司简介

Abbott Laboratories
F. Hoffmann-La Roche Ltd
DiaSorin SpA
Danaher Corp
Thermo Fisher Scientific Inc
PerkinElmer Inc
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
bioMerieux SA
Svar Life Science AB
Siemens Healthcare GmbH

第 13 章：附录

关于 Insight Partners
专业术语

Product Code: BMIRE00027857

The Asia Pacific immunodiagnostics market is expected to grow from US$ 2,409.90 million in 2023 to US$ 4,252.35 million by 2030. It is estimated to grow at a CAGR of 8.5% from 2023 to 2030.

Technological Advancements in Immunodiagnostics Drive Asia Pacific Industrial Robotics Market

The current trend in immunodiagnostics is microfluidics and magnetic beads with potential commercialization. These sensitive, specific, and time-saving methodologies are essential in understanding and diagnosing health conditions, such as infectious diseases, metabolic disorders, and cardiac problems.

The increasing applications of immunodiagnostics solutions encouraged the development of targeted treatments and therapies for precision health. The prominent market players also promote assay technologies, microfluidics, and magnetic beads. For immunoassays, magnetic particles, such as Sera-Mag beads, offer a convenient alternative to plate-based ELISAs, as both rely on the same assay principle. Merck KGaA launched the Magna Chip Protein A magnetic beads. This recombinant Protein A is covalently bound to magnetic beads for chromatin immunoprecipitations (Chip assays), providing users with a faster, reproducible, and more efficient reagent for collecting immunocomplexes than agarose beads.

In microfluidics, some immunodiagnostics target single biomarkers. However, a recent trend shows the detection of multiple analytes according to the complexity and the need to make early reliable diagnoses.

In September 2023, Siemens Healthineers released its new CE-marked SARS-CoV-2/FluA/FluB/HRSV assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test. The new FTD SARS-CoV-2/FluA/FluB/HRSV assay enables comprehensive and semi-automated molecular testing for seasonal respiratory pathogens. The combination PCR test detects and differentiates clinically relevant viruses such as SARS-CoV-2, Influenza A, Influenza B, and HRSV A/B.

Asia Pacific Immunodiagnostics Market Overview

According to Statista, a large chunk of the Chinese population was suffering from chronic diseases in 2020. Almost 80% of deaths among people aged 60 years in the country are caused due to chronic NCDs, of which the most severe are ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and Type II diabetes. According to China Blueprint, immunological diagnosis has exceeded biochemical diagnosis (accounting for 27%), and the in vitro diagnostics (IVD) market has gone mainstream in China. However, compared to developed countries, there is still room for alternative biochemical diagnosis to expand in China's immunodiagnostics market, as the average ratio of biochemical to immunization diagnosis is about 1:2, according to statistical data from several agencies. As technological innovation advances with the growing need for high-end testing, diagnostics is expected to consolidate its mainstream status.

Furthermore, collaborations between organizations are increasing for developing and producing assays. For instance, in December 2023, Ortho Clinical Diagnostics Trading and Shanghai Medconn Biotechnology signed an agreement as part of a joint venture to develop and manufacture assays for the VITROS immunodiagnostics platform in China. The expertise of Ortho Clinical Diagnostics Trading in developing and designing in vitro diagnostics (IVD) technologies for POC settings, clinical labs, and transfusion medicine will propel the growth of the Asia Pacific immunodiagnostics market in the coming years.

Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Immunodiagnostics Market Segmentation

The Asia Pacific immunodiagnostics market is segmented into product, clinical indication, end user, and country.

Based on product, the Asia Pacific immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered a largest share in the Asia Pacific immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Asia Pacific immunodiagnostics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered a largest share in the Asia Pacific immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Asia Pacific immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered a largest share in the Asia Pacific immunodiagnostics market.

Based on country, the Asia Pacific immunodiagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2023, China registered a largest share in the Asia Pacific immunodiagnostics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific immunodiagnostics market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific immunodiagnostics market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific immunodiagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the immunodiagnostics market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Asia Pacific Immunodiagnostics Market - by Product
- 1.3.2 Asia Pacific Immunodiagnostics Market - by Clinical Indication
- 1.3.3 Asia Pacific Immunodiagnostics Market - by End User
- 1.3.4 Asia Pacific Immunodiagnostics Market - by Country

2. Asia Pacific Immunodiagnostics Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Immunodiagnostics Market - Market Landscape

4.1 Overview
4.2 Asia Pacific PEST Analysis
4.3 Expert's Opinion

5. Asia Pacific Immunodiagnostics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Infectious Diseases
- 5.1.2 Growing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
- 5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
- 5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
5.4 Future Trends
- 5.4.1 Technological Advancements in Immunodiagnostics
5.5 Impact Analysis

6. Immunodiagnostics Market - Asia Pacific Analysis

6.1 Asia Pacific Immunodiagnostics Market Revenue Forecast and Analysis

7. Asia Pacific Immunodiagnostics Market Analysis - by Product

7.1 Overview
7.2 Asia Pacific Immunodiagnostics Market, By Product, 2022 & 2030 (%)
7.3 Enzyme-linked Immunosorbent Assays (ELISA)
- 7.3.1 Overview
- 7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
- 7.4.1 Overview
- 7.4.2 Chemiluminescence Immunoassays (CLIA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.3 Vitamin D Assay
  - 7.4.3.1 Overview
  - 7.4.3.2 Vitamin D Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.4 HIV Detection
  - 7.4.4.1 Overview
  - 7.4.4.2 HIV Detection: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.5 HIV Ag/Ab Combo assay
  - 7.4.5.1 Overview
  - 7.4.5.2 HIV Ag/Ab Combo Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.6 Other Tests
  - 7.4.6.1 Overview
  - 7.4.6.2 Other Tests: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Radioimmunoassays (RIA)
- 7.5.1 Overview
- 7.5.2 Radioimmunoassays (RIA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Immunodiagnostics Market Analysis - Clinical Indication

8.1 Overview
8.2 Asia Pacific Immunodiagnostics Market Share by Clinical Indication - 2022 & 2030 (%)
8.3 Infectious Diseases:
- 8.3.1 Overview
- 8.3.2 Infectious Diseases: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 COVID-19
    - 8.3.2.1.1 Overview
    - 8.3.2.1.2 COVID-19: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Tuberculosis
    - 8.3.2.2.1 Overview
    - 8.3.2.2.2 Tuberculosis: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.3 Lyme
    - 8.3.2.3.1 Overview
    - 8.3.2.3.2 Lyme: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.4 Infection Management
    - 8.3.2.4.1 Overview
    - 8.3.2.4.2 Infection Management: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.5 Zika
    - 8.3.2.5.1 Overview
    - 8.3.2.5.2 Zika: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.6 Treponema
    - 8.3.2.6.1 Overview
    - 8.3.2.6.2 Treponema: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.7 TORCH
    - 8.3.2.7.1 Overview
    - 8.3.2.7.2 TORCH: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.8 Measles and Mumps
    - 8.3.2.8.1 Overview
    - 8.3.2.8.2 Measles and Mumps: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.9 VZV
    - 8.3.2.9.1 Overview
    - 8.3.2.9.2 VZV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.10 EBV
    - 8.3.2.10.1 Overview
    - 8.3.2.10.2 EBV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.4 Hepatitis+HIV:
- 8.4.1 Overview
- 8.4.2 Hepatitis+HIV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Gastrointestinal
- 8.5.1 Overview
- 8.5.2 Gastrointestinal: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.6 Metabolic Disorders
- 8.6.1 Overview
- 8.6.2 Metabolics: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7 Endocrinology
- 8.7.1 Overview
- 8.7.2 Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.3 Hypertension
  - 8.7.3.1 Overview
  - 8.7.3.2 Hypertension: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.4 Growth
  - 8.7.4.1 Overview
  - 8.7.4.2 Growth: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.5 Diabetes
  - 8.7.5.1 Overview
  - 8.7.5.2 Diabetes: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.6 Thyroid
  - 8.7.6.1 Overview
  - 8.7.6.2 Thyroid: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.7 Reproductive Endocrinology
  - 8.7.7.1 Overview
  - 8.7.7.2 Reproductive Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Immunodiagnostics Market Analysis - End User

9.1 Overview
9.2 Asia Pacific Immunodiagnostics Market Share by End User - 2022 & 2030 (%)
9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 Hospitals: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Clinics
- 9.4.1 Overview
- 9.4.2 Clinics: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Diagnostic Laboratories
- 9.5.1 Overview
- 9.5.2 Diagnostic Laboratories: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.6 Academic and Research Institutes
- 9.6.1 Overview
- 9.6.2 Academic and Research Institutes: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.7 Others
- 9.7.1 Overview
- 9.7.2 Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Immunodiagnostics Market - Revenue and Forecast to 2030 - Country Analysis

10.1 Overview

11. Asia Pacific Immunodiagnostics Market -Industry Landscape

11.1 Overview
11.2 Inorganic Growth Strategies
- 11.2.1 Overview
11.3 Organic Growth Strategies
- 11.3.1 Overview

12. Company Profiles

12.1 Abbott Laboratories
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 DiaSorin SpA
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Danaher Corp
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 PerkinElmer Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 bioMerieux SA
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Svar Life Science AB
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Siemens Healthcare GmbH
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms

List Of Tables

Table 1. China Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 2. China Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 3. China Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 4. China Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 5. China Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 6. China Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 7. Japan Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 8. Japan Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 9. Japan Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 10. Japan: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 11. Japan Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 12. Japan Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 13. India Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 14. India Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 15. India Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 16. India: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 17. India Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 18. India Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 19. Australia Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 20. Australia Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 21. Australia Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 22. Australia: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 23. Australia Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 24. Australia Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 25. South Korea Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 26. South Korea Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 27. South Korea Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 28. South Korea: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 29. South Korea Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 30. South Korea Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Asia Pacific Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Asia Pacific Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of Asia Pacific Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 34. Rest of Asia Pacific: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 35. Rest of Asia Pacific Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 36. Rest of Asia Pacific Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 37. Recent Inorganic Growth Strategies in the Asia Pacific immunodiagnostics market
Table 38. Recent Organic Growth Strategies in the Asia Pacific immunodiagnostics market
Table 39. Glossary of Terms, Asia Pacific Immunodiagnostics Market

List Of Figures

Figure 1. Asia Pacific Immunodiagnostics Market Segmentation
Figure 2. Asia Pacific Immunodiagnostics Market, by Country
Figure 3. Asia Pacific Immunodiagnostics Market Overview
Figure 4. Enzyme-Linked Immunosorbent Assays (ELISA) Segment Held Largest Share of Product Segment in Asia Pacific Immunodiagnostics Market
Figure 5. India Expected to Show Remarkable Growth During Forecast Period
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Experts' Opinion
Figure 8. Asia Pacific Immunodiagnostics Market: Impact Analysis of Drivers and Restraints
Figure 9. Asia Pacific Immunodiagnostics Market - Revenue Forecast and Analysis - 2021-2030
Figure 10. Asia Pacific Immunodiagnostics Market, by Product, 2022 & 2030 (%)
Figure 11. Enzyme-linked Immunosorbent Assays (ELISA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 12. Chemiluminescence Immunoassays (CLIA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 13. Vitamin D Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 14. HIV Detection: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 15. HIV Ag/Ab Combo Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 16. Other Tests: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 17. Radioimmunoassays (RIA):Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 18. Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Immunodiagnostics Market Share by Clinical Indication - 2022 & 2030 (%)
Figure 20. Infectious Diseases: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 21. COVID-19: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 22. Tuberculosis: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 23. Lyme: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 24. Infection Management: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 25. Zika: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 26. Treponema: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 27. TORCH: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 28. Measles and Mumps: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 29. VZV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 30. EBV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 31. Hepatitis+HIV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 32. Gastrointestinal: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 33. Metabolics: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 34. Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 35. Hypertension: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 36. Growth: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 37. Diabetes: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 38. Thyroid: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 39. Reproductive Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 40. Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 41. Asia Pacific Immunodiagnostics Market Share by End User - 2022 & 2030 (%)
Figure 42. Hospitals: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 43. Clinics: Asia Pacific Immunodiagnostics Market Revenue and Forecasts To 2030 (US$ Million)
Figure 44. Diagnostic Laboratories: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 45. Academic and Research Institutes: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 46. Others: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 47. Asia Pacific: Immunodiagnostics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 48. Asia Pacific: Immunodiagnostics Market, by Country, 2022 & 2030 (%)
Figure 49. China: Immunodiagnostics market - Revenue and Forecast to 2030 (US$ Million)
Figure 50. Japan: Immunodiagnostics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 51. India: Immunodiagnostics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 52. Australia: Immunodiagnostics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 53. South Korea: Immunodiagnostics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 54. Rest of Asia Pacific: Immunodiagnostics Market - Revenue and Forecast to 2030 (US$ Million)